Drug Trial Radar · NCT00416520
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
Jun 2007
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
Conditions
- Chronic Kidney Disease
- Hyperphosphatemia
Interventions
MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)Drug
3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
PlaceboDrug
3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Another phosphate binder (Sevelamer)Drug
Current approved dosing recommendations for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2)Time frame: week16 minus week12
Locations
68 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Adelaide, Australia
Site not named
Nedlands, Australia
Site not named
Parkville, Australia
Site not named
St Leonards, Australia
Site not named
Sydney, Australia
Site not named
Woolloongabba, Australia
Site not named
Graz, Austria
Site not named
Frýdek-Místek, Czechia
Site not named
HradecKralove, Czechia
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Site not named
Tábor, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Bordeaux, France
Site not named
Montpelier, France
Site not named
Paris, France
Site not named
Aachen, Germany
Site not named
Aschaffenburg, Germany
Site not named
Coburg, Germany
Site not named
Coesfeld, Germany
Site not named
Darmstadt, Germany
Site not named
Dieburg, Germany
Site not named
Dortmund, Germany
Site not named
Düsseldorf, Germany
Site not named
Hamburg, Germany
Site not named
Homberg (Efze), Germany
Site not named
Langen, Germany
Site not named
Mannheim-Kafertal, Germany
Site not named
München, Germany
Site not named
Potsdam-Babelsberg, Germany
Site not named
Baja, Hungary
Site not named
Budapest, Hungary
Site not named
Kisvárda, Hungary
Site not named
Veszprém, Hungary
Site not named
Biella, Italy
Site not named
Como, Italy
Site not named
Cremona, Italy
Site not named
Lecco, Italy
Site not named
Livorno, Italy
Site not named
Milan, Italy
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.